Literature DB >> 20072653

Peritoneal adhesion and angiogenesis in ovarian carcinoma are inversely regulated by hyaluronan: the role of gonadotropins.

Yael Chagit Tzuman1, Stav Sapoznik, Dorit Granot, Nava Nevo, Michal Neeman.   

Abstract

Ovarian carcinoma is the leading cause of death among gynecologic cancers. Although transformation of the outer ovarian epithelium was linked with ovulation, the disease is significantly more prevalent and severe in postmenopausal women. We postulated that menopause could augment ovarian cancer progression through the effects of gonadotropins on multifocal seeding to the mesothelial layer lining the peritoneum. This seeding is mediated by integrins as well as by CD44 interaction with hyaluronan (HA). Here, we report the effect of gonadotropins on HA synthesis and degradation and on peritoneal adhesion. A significant concentration- and time-dependent induction in expression levels of HA synthases (HASs) and hyaluronidases (Hyals) was observed in vitro on stimulation of human epithelial ovarian carcinoma cells by gonadotropins. Hormonal regulation of HA-mediated adhesion was manifested in vivo as well, by fluorescence microscopy of stained MLS multicellular tumor spheroids. The number of spheroids adhered to the mesothelium of ovariectomized CD-1 nude mice 9.5 hours after intraperitoneal insertion was significantly higher than in nonovariectomized mice. Inhibition of HA synthesis by 6-diazo-5-oxo-1-norleucine (DON) both in spheroids and ovariectomized mice significantly reduced the number of adhered spheroids. Thus, the change in the hormonal environment during menopause assists in HA-dependent adherence of ovarian cancer spheroids onto the peritoneum. However, HA is antiangiogenic and it can significantly suppress tumor progression. Accordingly, angiogenesis of the adhered spheroids was significantly elevated in DON-treated tumors. These results can explain the selective pressure that can lead to simultaneously increased tumor expression of both HASs and Hyals.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20072653      PMCID: PMC2805883          DOI: 10.1593/neo.91272

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  42 in total

1.  Initial stages of cell-matrix adhesion can be mediated and modulated by cell-surface hyaluronan.

Authors:  Ella Zimmerman; Benjamin Geiger; Lia Addadi
Journal:  Biophys J       Date:  2002-04       Impact factor: 4.033

2.  Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies.

Authors:  Roberta B Ness; Daniel W Cramer; Marc T Goodman; Susanne Krûger Kjaer; Kathy Mallin; Berit Jul Mosgaard; David M Purdie; Harvey A Risch; Ronald Vergona; Anna H Wu
Journal:  Am J Epidemiol       Date:  2002-02-01       Impact factor: 4.897

3.  Hyaluronic acid as an anti-angiogenic shield in the preovulatory rat follicle.

Authors:  C Tempel; A Gilead; M Neeman
Journal:  Biol Reprod       Date:  2000-07       Impact factor: 4.285

Review 4.  The six hyaluronidase-like genes in the human and mouse genomes.

Authors:  A B Csoka; G I Frost; R Stern
Journal:  Matrix Biol       Date:  2001-12       Impact factor: 11.583

5.  Effect of reproductive hormones on ovarian epithelial tumors: I. Effect on cell cycle activity.

Authors:  Hong Zhou; Michelle Ping Luo; Axel H Schönthal; Malcolm C Pike; Michael R Stallcup; Martina Blumenthal; Wenxin Zheng; Louis Dubeau
Journal:  Cancer Biol Ther       Date:  2002 May-Jun       Impact factor: 4.742

6.  Gonadotropin stimulation of MLS human epithelial ovarian carcinoma cells augments cell adhesion mediated by CD44 and by alpha(v)-integrin.

Authors:  Yael S Schiffenbauer; Gila Meir; Miriam Maoz; Sharona Cohen Even-Ram; Rachel Bar-Shavit; Michal Neeman
Journal:  Gynecol Oncol       Date:  2002-02       Impact factor: 5.482

7.  Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women.

Authors:  Tomas Riman; Paul W Dickman; Staffan Nilsson; Nestor Correia; Hans Nordlinder; Cecilia M Magnusson; Elisabete Weiderpass; Ingemar R Persson
Journal:  J Natl Cancer Inst       Date:  2002-04-03       Impact factor: 13.506

8.  VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors.

Authors:  Jun Wang; Feng Luo; Jean J Lu; Peter K Chen; Paul Liu; Wenxin Zheng
Journal:  Int J Cancer       Date:  2002-01-10       Impact factor: 7.396

9.  Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer.

Authors:  J A Parrott; V Doraiswamy; G Kim; R Mosher; M K Skinner
Journal:  Mol Cell Endocrinol       Date:  2001-02-14       Impact factor: 4.102

10.  Menopausal hormone replacement therapy and risk of ovarian cancer.

Authors:  James V Lacey; Pamela J Mink; Jay H Lubin; Mark E Sherman; Rebecca Troisi; Patricia Hartge; Arthur Schatzkin; Catherine Schairer
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

View more
  12 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  Dinosaurs and ancient civilizations: reflections on the treatment of cancer.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

3.  Versican induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides.

Authors:  Miranda P Ween; Katja Hummitzsch; Raymond J Rodgers; Martin K Oehler; Carmela Ricciardelli
Journal:  Clin Exp Metastasis       Date:  2010-12-12       Impact factor: 5.150

4.  Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O-GlcNAc modification.

Authors:  Rie Jo; Hirotaka Shibata; Isao Kurihara; Kenichi Yokota; Sakiko Kobayashi; Ayano Murai-Takeda; Yuko Mitsuishi; Takeshi Hayashi; Toshifumi Nakamura; Hiroshi Itoh
Journal:  Hypertens Res       Date:  2022-10-14       Impact factor: 5.528

5.  Elevated expression of hyaluronic acid binding protein 1 (HABP1)/P32/C1QBP is a novel indicator for lymph node and peritoneal metastasis of epithelial ovarian cancer patients.

Authors:  Hongyang Yu; Qian Liu; Tao Xin; Lina Xing; Guanglu Dong; Qiuying Jiang; Yanju Lv; Xiaowei Song; Chong Teng; Dayong Huang; Yanju Li; Weixi Shen; Chong Teng; Yinghua Jin; Fubin Zhang
Journal:  Tumour Biol       Date:  2013-08-09

6.  Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

Review 7.  Role of versican, hyaluronan and CD44 in ovarian cancer metastasis.

Authors:  Miranda P Ween; Martin K Oehler; Carmela Ricciardelli
Journal:  Int J Mol Sci       Date:  2011-01-31       Impact factor: 5.923

8.  Effects of anti-CD44 monoclonal antibody IM7 carried with chitosan polylactic acid-coated nano-particles on the treatment of ovarian cancer.

Authors:  Yizhuo Yang; Xinghui Zhao; Xiuli Li; Zhifeng Yan; Zhongyu Liu; Yali Li
Journal:  Oncol Lett       Date:  2016-11-22       Impact factor: 2.967

Review 9.  Ovarian Cancer Dissemination-A Cell Biologist's Perspective.

Authors:  Sadaf Farsinejad; Thomas Cattabiani; Taru Muranen; Marcin Iwanicki
Journal:  Cancers (Basel)       Date:  2019-12-06       Impact factor: 6.639

Review 10.  Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research.

Authors:  Nuzhat Ahmed; Kaye L Stenvers
Journal:  Front Oncol       Date:  2013-09-25       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.